Breakthrough Therapy Designation from U.S. FDA for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer

Source Link:

https://ir.loxooncology.com/press-releases/2371557-Loxo-oncology-announces-receipt-of-breakthrough-therapy-designation-from-u.s.-food-and-drug-administration-for-loxo-292-for-the-treatment-of-ret-fusion-positive-thyroid-cancer